Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis

Annals of the New York Academy of Sciences

Volumn 1173, Issue , 2009, Pages 847-857

  Giorgini, Alessia ^a   Capsoni, Franco ^a   Podda, Mauro ^a   Lleó, Ana ^a,b   Battezzati, Pier Maria ^a   Ongari, Anna Maria ^a   Selmi, Carlo ^a   Benetti, Alberto ^a   Malinverno, Federica ^a   Rossaro, Lorenzo ^b   Gershwin, M Eric ^b   Zuin, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Leukocyte function; Opportunistic infection; Pegylated interferon; Ribavirin

Indexed keywords

COMPLEMENT COMPONENT C3 RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PEGINTERFERON ALPHA2A; REACTIVE OXYGEN METABOLITE; RIBAVIRIN;

ABSCESS; ADULT; AGED; ANEMIA; ANGINA PECTORIS; ANTIVIRAL THERAPY; BACTERIAL INFECTION; BREAST CANCER; CELL ACTIVITY; CELL COUNT; CELL ISOLATION; CELL SUBPOPULATION; CHEMOTAXIS; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROENTERITIS; GINGIVITIS; HEPATITIS C; HEPATITIS C VIRUS; HERPES LABIALIS; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; LEUKOCYTE COUNT; LEUKOCYTE FUNCTION; LIVER CIRRHOSIS; MALE; MONOCYTE; NEUTROPHIL CHEMOTAXIS; NEUTROPHIL COUNT; PHAGOCYTOSIS; PROTEIN BLOOD LEVEL; RESPIRATORY BURST; RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

HEPATITIS C VIRUS;

EID: 69949150187     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.04623.x     Document Type: Conference Paper

References (36)

1. www.fda.gov/ohrms/dockets/ac/02/briefing/3909b1.htm.
2. www.fda.gov/ohrms/dockets/ac/02/slides/3909S1- 03-FDA-Tauber/index.htm.
3. Puoti, M. et al. 2004. Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? Antivir. Ther. 9: 627-630.
4. Soza, A. et al. 2002. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 36: 1273-1279.
5. Fried, M.W. 2002. Side effects of therapy of hepatitis C and their management. Hepatology 36: S237-244.
6. Parana, R. et al. 2000. Severe strongyloidiasis during interferon plus ribavirin therapy for chronic HCV infection. Eur. J. Gastroenterol. Hepatol. 12: 245-246.
7. Vander, T. et al. 2003. Listeria monocytogenes meningitis in a patient with chronic hepatitis C infection, treated by interferon alfa and ribavirin. J. Infect. 46: 70-71.
8. Manns, M.P. et al. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus rib-avirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
9. Hadziyannis, S.J. et al. 2004. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140: 346-355.
10. Juarez-Navarro, A. et al. 2005. Incidence and severity of infections according to the development of neu-tropenia during combined therapy with pegylated interferon-alpha2a plus ribavirin in chronic hepatitis C infection. Methods Find Exp. Clin. Pharmacol. 27: 317-322.
11. Russo, M.W. & M.W. Fried. 2003. Side effects of therapy for chronic hepatitis C. Gastroenterology 124: 1711-1719.
12. Gyllenhammar, H. et al. 1988. Recombinant human leukocyte interferon modulates neutrophil function in vitro. J. Interferon Res. 8: 441-449.
13. Steele R.W. et al. 1988. Effects of ribavirin on neu-trophil function. Am. J. Med. Sci. 295: 503-506.
14. Kasimir, S., J. Brom & W. Konig. 1991. Effect of interferon-alpha on neutrophil functions. Immunology 74: 271-278.
15. Fukuda, A. et al. 2000. Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patients. Cytokines Cell. Mol. Ther. 6: 149-154.
16. Koie, T. et al. 2001. Effect of interferon-alpha on production of reactive oxygen species by human neu-trophils. Luminescence 16: 39-43.
17. Foster, G.R. et al. 2004. IFN-alpha subtypes differentially affect human T cell motility. J. Immunol. 173: 1663-1670.
18. Caliceti, P. 2004. Pharmacokinetics of pegylated in-terferons: what is misleading? Dig. Liver Dis. 36(Suppl 3): S334-339.
19. Boyum, A. 1968. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of gran-ulocytes by combining centrifugation and sedimentation at 1 g. Scand. J. Clin. Lab. Invest. Suppl. 97: 77-89.
20. Atzeni, F. et al. 2002. Induction of CD69 activation molecule on human neutrophils by GM-CSF, IFN-gamma, and IFN-alpha. Cell Immunol. 220: 20-29.
21. Capsoni, F. et al. 1992. Membrane expression and function of complement receptors CR1 and CR3 on neutrophils from HIV-infected subjects: modulation by rTNF-alpha and rGM-CSF. Scand. J. Immunol. 36: 541-546.
22. Peck-Radosavljevic, M. et al. 2002. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology 123: 141-151.
23. Wong, S. et al. 1996. A comparative trial of recom-binant interferon alpha 2A versus alpha 2 beta on myelosuppression in healthy adult volunteers. Hep-atogastroenterology 43: 301-305.
24. Fried, M.W. et al. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347: 975-982.
25. Zuin, M. et al. 2004. Prospective assessment of the incidence of infections during pegylated inter-feron (PEG-IFN) plus ribavirin (RBV) treatment for chronic hepatitis C (CHC). Hepatology 40: 329A.
26. Herberman, R.B. 1997. Effect of alpha-interferons on immune function. Semin Oncol. 24: S9-78-S9-80.
27. He, X.H., P.C. Shaw & S.C. Tam. 1999. Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation. Life Sci. 65: 355-368.
28. Little, R., M.R. White & K.L. Hartshorn. 1994. Interferon-alpha enhances neutrophil respiratory burst responses to stimulation with influenza A virus and FMLP. J. I n f e c t . D i s . 170: 802-810.
29. Laverman, P. et al. 2001. Microscopic localization of PEG-liposomes in a rat model of focal infection. J. Control Release 75: 347-355.
30. Glue, P. et al. 2000. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 32: 647-653.
31. Gordon, M.Y. et al. 1987. Compartmentalization of a haematopoietic growth factor (GM-CSF) by gly-cosaminoglycans in the bone marrow microenviron-ment. Nature 326: 403-405.
32. Roberts, R. et al. 1988. Heparan sulphate bound growth factors: a mechanism for stromal cell mediated haemopoiesis. Nature 332: 376-378.
33. Eisen-Vandervelde, A.L., Z.Q. Yao & Y.S. Hahn. 2004. The molecular basis of HCV-mediated immune dysregulation. Clin. Immunol. 111: 16-21.
34. Kacani, L. et al. 2000. Detachment of human immunodeficiency virus type 1 from germinal centers by blocking complement receptor type 2. J. V i r o l . 74: 7997-8002.
35. Williamson, D.F., R.A. Parker & J.S. Kendrick. 1989. The box plot: a simple visual method to interpret data. Ann. Intern. Med. 110: 916-921.
36. Wang, K. et al. 2003. Inhibition of neutrophil apop-tosis by type 1 IFN depends on cross-talk between phosphoinositol 3-kinase, protein kinase C-delta, and NF-kappa B signaling pathways. J. Immunol. 171(2): 1035-1041.